Phase
Condition
Depression
Mood Disorders
Affective Disorders
Treatment
Placebo
CYB003
Psychological Support
Clinical Study ID
Ages 18-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
Aged 18 to 85 years inclusive, at Screening
Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as perevaluation by the Investigator. The first MDD episode must have occurred prior toage 60.
Depression is of moderate to severe degree at Screening, independently confirmed byadditional clinical assessments
Participant has been on a stable dose of a single antidepressant medication at anadequate dose (label specified) for an adequate duration in the last 4 weeks priorto Screening and has had an inadequate response (less than 50% improvement), asjudged by the Investigator and clinical interviews.
Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤ 40 kg/m2),inclusive, at Screening.
Participant is able to refrain from nicotine use during the dosing session (up to 8hours)
Registered with a healthcare professional who can confirm the diagnosis and previoustreatments received by the participant.
Participants capable of producing sperm must use a condom during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person ofchildbearing potential. In addition, their partner of childbearing potential mustuse a highly effective method of contraception (i.e., failure rate less than 1% whenused consistently and correctly) from first dosing until 12 weeks following finaldosing.
Participants of childbearing potential who have a partner capable of producing spermmust agree to use a highly effective method of contraception (i.e., failure rateless than 1% when used consistently and correctly) in combination with the use of acondom plus spermicide during the trial and for 12 weeks after their final dose oftrial medication. Such participants must have a negative pregnancy test at Screeningand Day -1 prior to dosing.
Female participants who were capable of producing eggs (ova) must be postmenopausalor permanently sterile following hysterectomy, bilateral salpingectomy, andbilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for atleast 12 months, and a serum follicle-stimulating hormone level in the menopausalrange, unless the participant is taking hormone replacement therapy or is usinghormonal contraception.
Participant has provided written informed consent, which includes compliance withthe requirements and restrictions listed in the informed consent form.
Exclusion
Exclusion Criteria:
Participants with any of the following characteristics/conditions will be excluded from trial participation:
Current or previously diagnosed schizophrenia spectrum or other psychotic disorders,including schizophrenia, schizoaffective disorder, schizotypal disorder,schizophreniform disorder, brief psychotic disorder, attention deficit hyperactivitydisorder, current or previous history of bipolar disorder, or current borderlinepersonality disorder.
Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first degree relatives).
Significant suicide risk within the past 6 months, during the Screening Period, orat Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c)clinical assessment of significant suicidal risk during clinical interview; or (d)non-suicidal self-injury within 12 months of Screening.
Current or previous diagnosis of treatment-resistant MDD, defined as failure torespond to 2 or more antidepressant treatments of 2 different classes given at anadequate dose for an adequate duration as judged by the Investigator and clinicalinterview.
Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brainstimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant,mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or anantipsychotic or mood stabilizer for MDD.
Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline,lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 
Participant is able to refrain from nicotine use during the dosing session (up to 8
hours)
 
Registered with a healthcare professional who can confirm the diagnosis and previous
treatments received by the participant.
 
Participants capable of producing sperm must use a condom during the trial and for
 12 weeks after their final dose of trial medication, if their partner is a person of
childbearing potential. In addition, their partner of childbearing potential must
use a highly effective method of contraception (i.e., failure rate less than 1% when
used consistently and correctly) from first dosing until 12 weeks following final
dosing.
 
Participants of childbearing potential who have a partner capable of producing sperm
must agree to use a highly effective method of contraception (i.e., failure rate
less than 1% when used consistently and correctly) in combination with the use of a
condom plus spermicide during the trial and for 12 weeks after their final dose of
trial medication. Such participants must have a negative pregnancy test at Screening
and Day -1 prior to dosing.
 
Female participants who were capable of producing eggs (ova) must be postmenopausal
or permanently sterile following hysterectomy, bilateral salpingectomy, and
bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at
least 12 months, and a serum follicle-stimulating hormone level in the menopausal
range, unless the participant is taking hormone replacement therapy or is using
hormonal contraception.
 
Participant has provided written informed consent, which includes compliance with
the requirements and restrictions listed in the informed consent form.
 
 Exclusion Criteria:
 
 Participants with any of the following characteristics/conditions will be excluded from
 trial participation:
 
Current or previously diagnosed schizophrenia spectrum or other psychotic disorders,
including schizophrenia, schizoaffective disorder, schizotypal disorder,
schizophreniform disorder, brief psychotic disorder, attention deficit hyperactivity
disorder, current or previous history of bipolar disorder, or current borderline
personality disorder.
 
Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type
 1 (first degree relatives).
 
Significant suicide risk within the past 6 months, during the Screening Period, or
at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c)
clinical assessment of significant suicidal risk during clinical interview; or (d)
non-suicidal self-injury within 12 months of Screening.
 
Current or previous diagnosis of treatment-resistant MDD, defined as failure to
respond to 2 or more antidepressant treatments of 2 different classes given at an
adequate dose for an adequate duration as judged by the Investigator and clinical
interview.
 
Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain
stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
 
Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant,
mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or an
antipsychotic or mood stabilizer for MDD.
 
Participant report of (or if available in medical record) exposure to psilocin, or
 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline,
lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than
 4 times over the participant's lifetime or any psychedelic use within 12 monthsprior to Screening.
Clinically relevant history of abnormal physical health interfering with the trialas determined by medical history and physical examinations obtained during Screeningas judged by the Investigator (including but not limited to, neurological,cardiovascular, respiratory, gastrointestinal [including dyspepsia orgastroesophageal reflux disease], hepatic, or renal disorder).
Participants with renal insufficiency.
Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medicationwith no change in dosage for at least 12 weeks prior to Screening.
Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinicallyrelevant abnormal results for heart rate or blood pressure
History or clinical evidence of any disease and/or existence of any surgical ormedical condition which might interfere with the absorption, distribution,metabolism, or excretion of the trial medication.
Participant has a presence or relevant history of organic brain disorders (e.g.,epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmaldisease, brain tumor or other medical conditions associated with seizures orconvulsions).
Known sensitivity to psilocin and/or any excipients present in the formulation.
Participant is taking or has taken OTC doses of 5 hydroxytryptophan or St John'sWort within 45 days prior to trial medication administration.
Strenuous exercise within 48 hours prior to each clinic visit.
The participant has participated in a clinical trial and has received a medicationor a new chemical entity within 12 weeks prior to dosing of current trialmedication.
Participants capable of producing sperm who will not abstain from sperm donationbetween first dosing and 12 weeks after final dosing.
Participants of childbearing potential who are pregnant, breastfeeding, planning toconceive or unwilling to abstain from egg (ova) donation between first dosing and 12weeks after final dosing.
History of serotonin syndrome.
Unwilling to consent to audio and video recording of psychological support anddosing sessions.
Study Design
Connect with a study center
Scottsdale Research Institute
Phoenix, Arizona 85022
United StatesSite Not Available
Del Sol Research Management
Tucson, Arizona 85715
United StatesSite Not Available
Noble Clinical Research
Tucson, Arizona 85704
United StatesActive - Recruiting
CenExel CIT (Clinical Innovations, Inc)
Bellflower, California 90706
United StatesActive - Recruiting
Kadima Neuropsychiatry Institute
La Jolla, California 92037
United StatesActive - Recruiting
Kadima Neuropsychiatry Institute
LaJolla, California 92037
United StatesSite Not Available
Catalina Research Institute
Montclair, California 91763
United StatesSite Not Available
Excell Research, Inc
Oceanside, California 92056
United StatesSite Not Available
Open Mind Collective/UCSF Medical Center Mount Zion
San Francisco, California 94114
United StatesActive - Recruiting
Inland Psychiatric Medical Group Inc
San Juan Capistrano, California 92675
United StatesSite Not Available
Pacific Neuroscience Institute
Santa Monica, California 90404
United StatesSite Not Available
Mountain View Clinical Research
Denver, Colorado 80209
United StatesActive - Recruiting
Starlight Clinical Research
Evergreen, Colorado 80439
United StatesSite Not Available
Research Centers of America
Hollywood, Florida 33024
United StatesActive - Recruiting
K2 Medical Research-Maitland
Maitland, Florida 32751
United StatesSite Not Available
Floridian Neuroscience Institute
Miami, Florida 33135
United StatesActive - Recruiting
Innovative Clinical Research, INC
North Miami, Florida 33161
United StatesActive - Recruiting
Charter Research
Orlando, Florida 32803
United StatesSite Not Available
Clinical Neuroscience Solutions, Inc
Orlando, Florida 32801
United StatesActive - Recruiting
Combined Research Orlando Phase I-IV
Orlando, Florida 32807
United StatesSite Not Available
K2 Medical Research-Tampa
Tampa, Florida 32751
United StatesSite Not Available
Atlanta Center for Medical Research, CenExel
Atlanta, Georgia 30331
United StatesActive - Recruiting
CenExel iResearch Atlanta
Decatur, Georgia 30330
United StatesActive - Recruiting
CenExel iResearch Savannah
Savannah, Georgia 31405
United StatesSite Not Available
Great Lakes Clinical Trials, DBA Flourish Research
Chicago, Illinois 60640
United StatesSite Not Available
Uptown Research Institute
Chicago, Illinois 60640
United StatesActive - Recruiting
Psychiatric Medicine Associates, LLC
Skokie, Illinois 60076
United StatesSite Not Available
DelRicht Research
New Orleans, Louisiana 70115
United StatesSite Not Available
Sunstone Medical, PC
Rockville, Maryland 20850
United StatesActive - Recruiting
Adams Clinical
Boston, Massachusetts 02472
United StatesActive - Recruiting
Adams Clinical Boston
Boston, Massachusetts 02116
United StatesSite Not Available
Elixia Health
Springfield, Massachusetts 01103
United StatesSite Not Available
Oasis Clinical Trials
Las Vegas, Nevada 89121
United StatesActive - Recruiting
Redbird Research, LLC
Las Vegas, Nevada 89119
United StatesSite Not Available
Global Medical Institues, Princeton Medical Institute
Princeton, New Jersey 08540
United StatesSite Not Available
Adams Clinical Bronx
Bronx, New York 10461
United StatesSite Not Available
Adams Clinical Harlem
New York, New York 100029
United StatesSite Not Available
Nautilus Psychiatric Services, PLLC
New York, New York 10017
United StatesSite Not Available
Monroe Biomedical Research
Monroe, North Carolina 28112
United StatesSite Not Available
Neurobehavioral Clinical Research
North Canton, Ohio 44720
United StatesActive - Recruiting
Clinical Neuroscience Solutions, CNS Healthcare
Memphis, Tennessee 38119
United StatesSite Not Available
HCA Healthcare/Medical City Green Oaks
Dallas, Texas 75251
United StatesSite Not Available
InSite Clinical Research, LLC
DeSota, Texas 75115
United StatesSite Not Available
InSite Clinical Research, LLC
DeSoto, Texas 75115
United StatesActive - Recruiting
Zillan Clinical Research
Houston, Texas 77433
United StatesSite Not Available
AIM Trials
Plano, Texas 75093
United StatesSite Not Available
Cedar Clinical Research
Murray, Utah 84107
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.